EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bimekizumab Efficacy by Patient Subgroups in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results from BE HEARD EXT

Christopher J. Sayed, Martina L. Porter, Alejandro Molina-Leyva, Jacek C. Szepietowski, Yosuke Ishitsuka, Evelina Van Ree, Christina Crater, Tom Vaux, Georgios Kokolakis

SKIN The Journal of Cutaneous Medicine · 14.07.2026 · 10 (4) · s796

DOI: 10.25251/8cabeg12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 14.07.2026. Verfasst von Christopher J. Sayed und 8 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Response to hidradenitis suppurativa (HS) treatment can vary depending on patient characteristics, necessitating new treatments with consistent efficacy.1 Bimekizumab is a humanized IgG1 monoclonal antibody that inhibits interleukin (IL)-17F in addition to IL-17A registered for the treatment of HS.2 Here, we report bimekizumab efficacy outcomes across different subgroups in patients with moderate to severe HS over 3 years. We aim to assess the maintenance of clinical response over 3 years with bimekizumab by age, sex, disease duration, Hurley Stage, and body mass index (BMI). Procedure/Study Data were pooled from the BE HEARD I&II (BHI&II) studies and their open-label extension, BE HEARD EXT (BHEXT).3,4 Proportions of patients achieving ≥50%/75% HiSCR (HiSCR50/75) in subgroups (age [

Zitieren

APA

Sayed, C. J., Porter, M. L., Molina-Leyva, A., Szepietowski, J. C., Ishitsuka, Y., Ree, E. V., Crater, C., Vaux, T., & Kokolakis, G. (2026). Bimekizumab Efficacy by Patient Subgroups in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results from BE HEARD EXT. SKIN The Journal of Cutaneous Medicine, 10(4), s796. https://doi.org/10.25251/8cabeg12

Vancouver

Sayed CJ, Porter ML, Molina-Leyva A, Szepietowski JC, Ishitsuka Y, Ree EV, et al. Bimekizumab Efficacy by Patient Subgroups in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results from BE HEARD EXT. SKIN The Journal of Cutaneous Medicine. 2026;10(4):s796. doi:10.25251/8cabeg12

BibTeX
@article{Sayed2026,
  author = {Sayed, Christopher J. and Porter, Martina L. and Molina-Leyva, Alejandro and Szepietowski, Jacek C. and Ishitsuka, Yosuke and Ree, Evelina Van and Crater, Christina and Vaux, Tom and Kokolakis, Georgios},
  title = {Bimekizumab Efficacy by Patient Subgroups in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results from BE HEARD EXT},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {4},
  pages = {s796},
  doi = {10.25251/8cabeg12}
}
Kostenlos starten →